[Effect of pressure on palatal soft tissue: histological study].

M. Ai

1980-12-01

Abstract:

What problem does this paper attempt to address?

Transformative Technology for FLASH Radiation Therapy: A Snowmass 2021 White Paper

Salime Boucher,Eric Esarey,Cameron Geddes,Carol Johnstone,Sergey Kutsaev,Billy W. Loo,Francois Méot,Brahim Mustapha,Kei Nakamura,Emilio Nanni,Lieselotte Obst-Huebl,Stephen E. Sampayan,Carl Schroeder,Reinhard Schulte,Ke Sheng,Antoine Snijders,Emma Snively,Sami G. Tantawi,Jeroen van Tilborg,Billy W. Loo Jr

DOI: https://doi.org/10.48550/arXiv.2203.11047

IF: 4.506

2022-03-21

Medical Physics

Abstract:Conventional cancer therapies include surgery, radiation therapy, chemotherapy, and, more recently, immunotherapy. These modalities are often combined to improve the therapeutic index. The general concept of radiation therapy is to increase the therapeutic index by creating a physical dose differential between tumors and normal tissues through precision dose targeting, image guidance, and high radiation beams that deliver radiation dose with high conformality, e.g., protons and ions. However, treatment and cure are still limited by normal tissue radiation toxicity, with many patients experiencing acute and long-term side effects. Recently, however, a fundamentally different paradigm for increasing the therapeutic index of radiation therapy has emerged, supported by preclinical research, and based on the FLASH radiation effect. FLASH radiation therapy (FLASH-RT) is an ultra-high dose-rate delivery of a therapeutic radiation dose within a fraction of a second. Experimental studies have shown that normal tissues seem to be universally spared at these high dose rates, whereas tumors are not. The dose delivery conditions are not yet fully characterized. Still, it is currently estimated that large doses of 10 Gy or more delivered in 200 ms or less produce normal tissue sparing effects yet effectively kill tumor cells. There is a great opportunity, but also many technical challenges, for the accelerator community to create the required dose rates with novel and compact accelerators to ensure the safe delivery of FLASH radiation beams.
FLASH: New intersection of physics, chemistry, biology, and cancer medicine

Marie-Catherine Vozenin,Billy W. Loo,Sami Tantawi,Peter G. Maxim,Douglas R. Spitz,Claude Bailat,Charles L. Limoli

DOI: https://doi.org/10.1103/revmodphys.96.035002

IF: 50.485

2024-09-21

Reviews of Modern Physics

Abstract:Ultrahigh dose rate, FLASH radiotherapy has emerged as one of the most promising innovations over the past decade in the field of radiation oncology, with the potential to eradicate radiation resistant primary tumors and improve the therapeutic outcome for cancer patients. FLASH is based on delivering radiation doses at ultrahigh dose rates (UHDR; >40 Gy/s ), more than 1000 times faster than irradiation at conventional dose rates (CONV). The experimental evidence demonstrating the differential effect of dose rate modulation on tumors and normal tissue is reviewed. Preclinical data consistently show that the antitumor efficacy of cytotoxic doses is not dependent on dose rate, but in normal tissues UHDR significantly reduces normal tissue toxicities compared to CONV, as observed in vivo . These observations define the FLASH effect. The FLASH effect has been reported to occur when using single or hypofractionated dose regimens in several experimental animal models (mice, rat, zebrafish, pig, and cats) and in multiple organs (lung, skin, gut, and brain) by numerous groups worldwide. Note that the FLASH effect has been demonstrated with electron, photon, and hadron (proton and heavier ion) beams. The current status and future technological development are reviewed, with an emphasis on critical beam parameters, future beam modalities, and prerequisites for safe clinical translation in terms of dosimetry, radioprotection, and treatment planning systems. Mechanistic investigations at the physicochemical and biological levels are presented, as are strategies to support and initiate clinical translation. This comprehensive review provides multidisciplinary radiation scientists with a road map of the technological, physical, chemical, biological, and clinical considerations that have made FLASH topical. These considerations are presented with a realistic and practical backdrop of the limitations and challenges that lie ahead. https://doi.org/10.1103/RevModPhys.96.035002 © 2024 American Physical Society

physics, multidisciplinary
FLASH Radiation Therapy — Key physical irradiation parameters and beam characteristics

Roya Boudaghi Malidarreh,Hesham M.H. Zakaly

DOI: https://doi.org/10.1088/1748-0221/19/02/p02035

2024-02-28

Journal of Instrumentation

Abstract:FLASH-RT represents a novel therapeutic radiation modality that holds remarkable potential for mitigating radiation therapy's adverse side effects. This cutting-edge technology allows for sparing healthy tissue while precisely targeting cancerous cells. This is possible by administering an ultra-high-dose-rate in less than a few hundred milliseconds. FLASH-RT has demonstrated impressive results in small-animal models, prompting scientists to adapt and advance existing technologies to make it a viable treatment option for humans. However, producing the ultra-high-dose-rate radiation required for the therapy remains a significant challenge. Several radiation sources, such as very high energy electrons (VHEEs), low energy electrons, x-rays, and protons, have been studied for their ability to deliver the necessary dose. Among them, FLASH-x-ray has gained the most attention owing to its capacity to penetrate deep-seated tumors. Despite the complexity of the process, the potential advantages of FLASH-RT made it an exciting area of research. To achieve the FLASH effect, high-frequency, pulsed irradiated accelerator technology can be employed. Sparing healthy tissue may allow for more aggressive and effective cancer treatments, leading to a better quality of life for patients. Ongoing research and development will be necessary to refine and optimize this approach to radiation therapy.

instruments & instrumentation
Framework for Quality Assurance of Ultra-High Dose Rate Clinical Trials Investigating FLASH Effects and Current Technology Gaps

Wei Zou,Rongxiao Zhang,Emil Schüler,Paige A Taylor,Anthony E Mascia,Eric S Diffenderfer,Tianyu Zhao,Ahmet S Ayan,Manju Sharma,Shu-Jung Yu,Weiguo Lu,Walter R Bosch,Christina Tsien,Murat Surucu,Julianne M Pollard-Larkin,Jan Schuemann,Eduardo G Moros,Magdalena Bazalova-Carter,David J Gladstone,Heng Li,Charles B Simone,Kristoffer Petersson,Stephen F Kry,Amit Maity,Billy W Loo,Lei Dong,Peter G Maxim,Ying Xiao,Jeffrey C Buchsbaum,Emil Schueler

DOI: https://doi.org/10.1016/j.ijrobp.2023.04.018

IF: 8.013

2023-04-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:FLASH radiation therapy (FLASH-RT), delivered with ultrahigh dose rate (UHDR), may allow patients to be treated with less normal tissue toxicity for a given tumor dose compared with currently used conventional dose rate. Clinical trials are being carried out and are needed to test whether this improved therapeutic ratio can be achieved clinically. During the clinical trials, quality assurance and credentialing of equipment and participating sites, particularly pertaining to UHDR-specific aspects, will be crucial for the validity of the outcomes of such trials. This report represents an initial framework proposed by the NRG Oncology Center for Innovation in Radiation Oncology FLASH working group on quality assurance of potential UHDR clinical trials and reviews current technology gaps to overcome. An important but separate consideration is the appropriate design of trials to most effectively answer clinical and scientific questions about FLASH. This paper begins with an overview of UHDR RT delivery methods. UHDR beam delivery parameters are then covered, with a focus on electron and proton modalities. The definition and control of safe UHDR beam delivery and current and needed dosimetry technologies are reviewed and discussed. System and site credentialing for large, multi-institution trials are reviewed. Quality assurance is then discussed, and new requirements are presented for treatment system standard analysis, patient positioning, and treatment planning. The tables and figures in this paper are meant to serve as reference points as we move toward FLASH-RT clinical trial performance. Some major questions regarding FLASH-RT are discussed, and next steps in this field are proposed. FLASH-RT has potential but is associated with significant risks and complexities. We need to redefine optimization to focus not only on the dose but also on the dose rate in a manner that is robust and understandable and that can be prescribed, validated, and confirmed in real time. Robust patient safety systems and access to treatment data will be critical as FLASH-RT moves into the clinical trials.

oncology,radiology, nuclear medicine & medical imaging
A potential revolution in cancer treatment: A topical review of FLASH radiotherapy

Yuan Gao,Ruirui Liu,Chih‐Wei Chang,Serdar Charyyev,Jun Zhou,Jeffrey D. Bradley,Tian Liu,Xiaofeng Yang

DOI: https://doi.org/10.1002/acm2.13790

2022-09-29

Journal of applied clinical medical physics [electronic resource] / American College of Medical Physics

Abstract:FLASH radiotherapy (RT) is a novel technique in which the ultrahigh dose rate (UHDR) (≥40 Gy/s) is delivered to the entire treatment volume. Recent outcomes of in vivo studies show that the UHDR RT has the potential to spare normal tissue without sacrificing tumor control. There is a growing interest in the application of FLASH RT, and the ultrahigh dose irradiation delivery has been achieved by a few experimental and modified linear accelerators. The underlying mechanism of FLASH effect is yet to be fully understood, but the oxygen depletion in normal tissue providing extra protection during FLASH irradiation is a hypothesis that attracts most attention currently. Monte Carlo simulation is playing an important role in FLASH, enabling the understanding of its dosimetry calculations and hardware design. More advanced Monte Carlo simulation tools are under development to fulfill the challenge of reproducing the radiolysis and radiobiology processes in FLASH irradiation. FLASH RT may become one of standard treatment modalities for tumor treatment in the future. This paper presents the history and status of FLASH RT studies with a focus on FLASH irradiation delivery modalities, underlying mechanism of FLASH effect, in vivo and vitro experiments, and simulation studies. Existing challenges and prospects of this novel technique are discussed in this manuscript.
FLASH Radiotherapy: History and Future

Binwei Lin,Feng Gao,Yiwei Yang,Dai Wu,Yu Zhang,Gang Feng,Tangzhi Dai,Xiaobo Du

DOI: https://doi.org/10.3389/fonc.2021.644400

IF: 4.7

2021-05-25

Frontiers in Oncology

Abstract:The biological effects of radiation dose to organs at risk surrounding tumor target volumes are a major dose-limiting constraint in radiotherapy. This can mean that the tumor cannot be completely destroyed, and the efficacy of radiotherapy will be decreased. Thus, ways to reduce damage to healthy tissue has always been a topic of particular interest in radiotherapy research. Modern radiotherapy technologies such as helical tomotherapy (HT), intensity-modulated radiation therapy (IMRT), and proton radiotherapy can reduce radiation damage to healthy tissues. Recent outcomes of animal experiments show that FLASH radiotherapy (FLASH-RT) can reduce radiation-induced damage in healthy tissue without decreasing antitumor effectiveness. The very short radiotherapy time compared to that of conventional dose-rate radiotherapy is another advantage of FLASH-RT. The first human patient received FLASH-RT in Switzerland in 2018. FLASH-RT may become one of the main radiotherapy technologies in clinical applications in the future. We summarize the history of the development of FLASH-RT, its mechanisms, its influence on radiotherapy, and its future.

oncology
Navigating the Critical Translational Questions for Implementing FLASH in the Clinic

Billy W Loo Jr,Ioannis I Verginadis,Brita Singers Sørensen,Anthony E Mascia,John P Perentesis,Albert C Koong,Emil Schüler,Erinn B Rankin,Peter G Maxim,Charles L Limoli,Marie-Catherine Vozenin

DOI: https://doi.org/10.1016/j.semradonc.2024.04.008

Abstract:The "FLASH effect" is an increased therapeutic index, that is, reduced normal tissue toxicity for a given degree of anti-cancer efficacy, produced by ultra-rapid irradiation delivered on time scales orders of magnitude shorter than currently conventional in the clinic for the same doses. This phenomenon has been observed in numerous preclinical in vivo tumor and normal tissue models. While the underlying biological mechanism(s) remain to be elucidated, a path to clinical implementation of FLASH can be paved by addressing several critical translational questions. Technological questions pertinent to each beam type (eg, electron, proton, photon) also dictate the logical progression of experimentation required to move forward in safe and decisive clinical trials. Here we review the available preclinical data pertaining to these questions and how they may inform strategies for FLASH cancer therapy clinical trials.
Effect of tight junctional resistance on penetration of LLC-PK1 epithelial cell layers by metastatic B16-F10 melanoma cells.

K. G. Conn,K. Knudsen

IF: 11.2

1989-12-15

Cancer Research

Abstract:The relationship between tight junctional resistance of a tissue and its penetration by metastatic cells was examined in vitro using LLC-PK1 cells, an epithelial cell line derived from pig kidney, and B16-F10 cells, a murine melanoma cell line metastatic in syngeneic C57BL/6 mice. When grown to confluence on 8.0-microns pore size polycarbonate filters, LLC-PK1 cells formed tight junctions between adjacent cells which offered an electrical resistance to a nondestructive 20-mu ampere alternating current passed across the cell layer. B16-F10 cells seeded on top of an LLC-PK1 epithelial layer with a measured transepithelial resistance of approximately 300 omega x cm2 were unable to penetrate the epithelial barrier. The tumor-promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) lowered the electrical resistance of the epithelial layer by 80% and simultaneously opened the epithelial barrier to penetration by metastatic cells.
Ultrahigh dose-rate (FLASH) x-ray irradiator for pre-clinical laboratory research

Mohammad Rezaee,Iulian Iordachita,John W Wong

DOI: https://doi.org/10.1088/1361-6560/abf2fa

IF: 3.5

2021-04-23

Physics in Medicine and Biology

Abstract:Abstract FLASH irradiation has been shown to reduce significantly normal tissue toxicity compared to conventional irradiation, while maintaining tumor control probability at similar level. Clinical translation of FLASH irradiation necessitates comprehensive laboratory studies to elucidate biological effects as well as pertinent technological and physical requirements. At present, FLASH research employs complex accelerator technologies of limited accessibilities. Here, we study the feasibility of a novel self-shielded x-ray irradiation cabinet system, as an enabling technology to enhance the preclinical research capabilities. The proposed system employs two commercially available high capacity 150 kVp fluoroscopy x-ray sources with rotating anode technology in a parallel-opposed arrangement. Simulation was performed with the GEANT4 Monte-Carlo platform. Simulated dosimetric properties of the x-ray beam for both FLASH and conventional dose-rate irradiations were characterized. Dose and dose rate from a single kV x-ray fluoroscopy source in solid water phantom were verified with measurements using Gafchromic films. The parallel-opposed x-ray sources can deliver over 50 Gy doses to a 20 mm thick water equivalent medium at ultrahigh dose-rates of 40–240 Gy s −1 . A uniform depth-dose rate (±5%) is achieved over 8–12 mm in the central region of the phantom. Mirrored beams minimize heel effect of the source and achieve reasonable cross-beam uniformity (±3%). Conventional dose-rate irradiation (≤0.1 Gy s −1 ) can also be achieved by reducing the tube current and increasing the distance between the phantom and tubes. The rotating anode x-ray source can be used to deliver both FLASH and conventional dose-rate irradiations with the field dimensions well suitable for small animal and cell-culture irradiations. For FLASH irradiation using parallel-opposed sources, entrance and exit doses can be higher by 30% than the dose at the phantom center. Beam angling can be employed to minimize the high surface doses. Our proposed system is amendable to self-shielding and enhance research in regular laboratory setting.

engineering, biomedical,radiology, nuclear medicine & medical imaging
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?

Keith A Cengel,Michele M Kim,Eric S Diffenderfer,Theresa M Busch,Keith A. Cengel,Michele M. Kim,Eric S. Diffenderfer,Theresa M. Busch

DOI: https://doi.org/10.1016/j.semradonc.2024.02.001

IF: 5.421

2024-04-01

Seminars in Radiation Oncology

Abstract:FLASH is an emerging treatment paradigm in radiotherapy (RT) that utilizes ultra-high dose rates (UHDR; >40 Gy)/s) of radiation delivery. Developing advances in technology support the delivery of UHDR using electron and proton systems, as well as some ion beam units (eg, carbon ions), while methods to achieve UHDR with photons are under investigation. The major advantage of FLASH RT is its ability to increase the therapeutic index for RT by shifting the dose response curve for normal tissue toxicity to higher doses. Numerous preclinical studies have been conducted to date on FLASH RT for murine sarcomas, alongside the investigation of its effects on relevant normal tissues of skin, muscle, and bone. The tumor control achieved by FLASH RT of sarcoma models is indistinguishable from that attained by treatment with standard RT to the same total dose. FLASH's high dose rates are able to mitigate the severity or incidence of RT side effects on normal tissues as evaluated by endpoints ranging from functional sparing to histological damage. Large animal studies and clinical trials of canine patients show evidence of skin sparing by FLASH vs. standard RT, but also caution against delivery of high single doses with FLASH that exceed those safely applied with standard RT. Also, a human clinical trial has shown that FLASH RT can be delivered safely to bone metastasis. Thus, data to date support continued investigations of clinical translation of FLASH RT for the treatment of patients with sarcoma. Toward this purpose, hypofractionated irradiation schemes are being investigated for FLASH effects on sarcoma and relevant normal tissues.

oncology,radiology, nuclear medicine & medical imaging
The FLASH effect—an evaluation of preclinical studies of ultra-high dose rate radiotherapy

Josie May McGarrigle,Kenneth Richard Long,Yolanda Prezado

DOI: https://doi.org/10.3389/fonc.2024.1340190

IF: 4.7

2024-04-23

Frontiers in Oncology

Abstract:FLASH radiotherapy (FLASH-RT) is a novel radiotherapy approach based on the use of ultra-high dose radiation to treat malignant cells. Although tumours can be reduced or eradicated using radiotherapy, toxicities induced by radiation can compromise healthy tissues. The FLASH effect is the observation that treatment delivered at an ultra-high dose rate is able to reduce adverse toxicities present at conventional dose rates. While this novel technique may provide a turning point for clinical practice, the exact mechanisms underlying the causes or influences of the FLASH effect are not fully understood. The study presented here uses data collected from 41 experimental investigations (published before March 2024) of the FLASH effect. Searchable databases were constructed to contain the outcomes of the various experiments in addition to values of beam parameters that may have a bearing on the FLASH effect. An in-depth review of the impact of the key beam parameters on the results of the experiments was carried out. Correlations between parameter values and experimental outcomes were studied. Pulse Dose Rate had positive correlations with almost all end points, suggesting viability of FLASH-RT as a new modality of radiotherapy. The collective results of this systematic review study suggest that beam parameter qualities from both FLASH and conventional radiotherapy can be valuable for tissue sparing and effective tumour treatment.

oncology
Immunoglobulins and complement factors in senile plaques

P. Eikelenboom,F. Stam

DOI: https://doi.org/10.1007/BF00685397

IF: 15.887

1982-06-01

Acta Neuropathologica

Abstract:
FLASH radiotherapy: ultra-high dose rates to spare healthy tissue

R M de Kruijff

DOI: https://doi.org/10.1080/09553002.2020.1704912

Abstract:A recent addition to the treatment options in external beam therapy, so-called FLASH radiotherapy, shows remarkable healthy-tissue-sparing properties in a number of pre-clinical studies without impacting the overall treatment efficacy. Its potential in clinical applications is attracting a great deal of interest in the medical community. The use of ultra-high dose rates at extremely short irradiation times has been shown to significantly enhance the differential effects between normal and tumor tissue. This makes it possible to increase treatment doses without further harming the surrounding healthy tissue. While most studies to date have focused on the use of electron beams, X-ray and proton FLASH radiotherapy have also shown beneficial effects, although for these latter two the results still need to be independently confirmed. Furthermore, the mechanisms underlying the biological effects remain to be elucidated. Very recently, the FLASH effect has been demonstrated in the first human patient, with promising results, supporting further clinical studies. This review will present an overview of the investigations into FLASH radiotherapy to date.
Dosimetry for FLASH Radiotherapy: A Review of Tools and the Role of Radioluminescence and Cherenkov Emission

Muhammad Ramish Ashraf,Mahbubur Rahman,Rongxiao Zhang,Benjamin B. Williams,David J. Gladstone,Brian W. Pogue,Petr Bruza

DOI: https://doi.org/10.3389/fphy.2020.00328

IF: 3.718

2020-08-21

Frontiers in Physics

Abstract:While spatial dose conformity delivered to a target volume has been pushed to its practical limits with advanced treatment planning and delivery, investigations in novel temporal dose delivery are unfolding new mechanisms. Recent advances in ultra-high dose radiotherapy, abbreviated as FLASH, indicate the potential for reduction in healthy tissue damage while preserving tumor control. FLASH therapy relies on very high dose rate of > 40Gy/s with sub-second temporal beam modulation, taking a seemingly opposite direction from the conventional paradigm of fractionated therapy. FLASH brings unique challenges to dosimetry, beam control, and verification, as well as complexity of radiobiological effective dose through altered tissue response. In this review, we compare the dosimetric methods capable of operating under high dose rate environments. Due to excellent dose-rate independence, superior spatial (~ <1 mm) and temporal (~ns) resolution achievable with Cherenkov and scintillation-based detectors, we show that luminescent detectors have a key role to play in the development of FLASH, as the field rapidly progresses toward clinical adaptation. Additionally, we show that the unique ability of certain luminescence-based methods to provide tumor oxygenation maps in real-time with submillimeter resolution can elucidate the radiobiological mechanisms behind the FLASH effect. In particular, such techniques will be crucial for understanding the role of oxygen in mediating the FLASH effect.

physics, multidisciplinary
Emergence of FLASH‐radiotherapy across the last 50 years (Review)

Menghua Li,Sen Zhou,Guofu Dong,Changzhen Wang

DOI: https://doi.org/10.3892/ol.2024.14735

2024-10-13

Oncology Letters

Abstract:A novel radiotherapy (RT) approach termed FLASH‐RT, which irradiates areas at ultra‐high dose rates, is of current interest to medical researchers. FLASH‐RT can maintain equivalent antitumor effects while sparing healthy tissue compared with conventional RT (CONV‐RT), which uses low dose rates. The sparing effect on healthy tissue after FLASH‐RT is known as the FLASH effect. Owing to the FLASH effect, FLASH‐RT can raise the maximum tolerable dose to control tumor growth or eradicate the tumor and provide a new strategy for clinical RT. However, definitive irradiation conditions for reproducing the FLASH effect and the biological mechanism of the FLASH effect have not yet been fully elucidated. The efficacy of FLASH‐RT is controversial despite its successful application in clinical RT. The present review recapitulates the progression of FLASH‐RT and critically comments on the hypothesis of the FLASH effect. In addition, the review expounds on the current issues with regard to the differential phenomena between in vitro and in vivo studies, and elaborates on the challenges for the application of FLASH‐RT that need to be addressed in the future.

oncology
FLASH radiotherapy: A new milestone in the field of cancer radiotherapy

Rui Tang,Jianqiong Yin,Yuanxin Liu,Jianxin Xue

DOI: https://doi.org/10.1016/j.canlet.2024.216651

2024-04-10

Abstract:Radiotherapy plays a pivotal role in the control and eradication of tumors, but it can also induce radiation injury to surrounding normal tissues while targeting tumor cells. In recent years, FLASH-Radiotherapy (FLASH-RT) has emerged as a cutting-edge research focus in the field of radiation therapy. By delivering high radiation doses to the treatment target in an ultra-short time, FLASH-RT produces the FLASH effect, which reduces the toxicity to normal tissues while achieving comparable tumor control efficacy to conventional radiotherapy. This review provides a brief overview of the development history of FLASH-RT and its impact on tumor control. Additionally, it focuses on introducing the protective effects and molecular mechanisms of this technology on various normal tissues, as well as exploring its synergistic effects when combined with other tumor therapies. Importantly, this review discusses the challenges faced in translating FLASH-RT into clinical practice and outlines its promising future applications.
Democratizing FLASH Radiotherapy

Michele Moreau,Serena Mao,Uriel Ngwa,Sayeda Yasmin-Karim,Debarghya China,Hamed Hooshangnejad,Daniel Sforza,Kai Ding,Heng Li,Mohammad Rezaee,Amol K Narang,Wilfred Ngwa

DOI: https://doi.org/10.1016/j.semradonc.2024.05.001

Abstract:FLASH radiotherapy (RT) is emerging as a potentially revolutionary advancement in cancer treatment, offering the potential to deliver RT at ultra-high dose rates (>40 Gy/s) while significantly reducing damage to healthy tissues. Democratizing FLASH RT by making this cutting-edge approach more accessible and affordable for healthcare systems worldwide would have a substantial impact in global health. Here, we review recent developments in FLASH RT and present perspective on further developments that could facilitate the democratizing of FLASH RT. These include upgrading and validating current technologies that can deliver and measure the FLASH radiation dose with high accuracy and precision, establishing a deeper mechanistic understanding of the FLASH effect, and optimizing dose delivery conditions and parameters for different types of tumors and normal tissues, such as the dose rate, dose fractionation, and beam quality for high efficacy. Furthermore, we examine the potential for democratizing FLASH radioimmunotherapy leveraging evidence that FLASH RT can make the tumor microenvironment more immunogenic, and parallel developments in nanomedicine or use of smart radiotherapy biomaterials for combining RT and immunotherapy. We conclude that the democratization of FLASH radiotherapy represents a major opportunity for concerted cross-disciplinary research collaborations with potential for tremendous impact in reducing radiotherapy disparities and extending the cancer moonshot globally.
Expectations, Challenges, and Current Knowledge

Andrea Borghini,Luca Labate,Simona Piccinini,Costanza Maria Vittoria Panaino,Maria Grazia Andreassi,Leonida Antonio Gizzi

DOI: https://doi.org/10.3390/ijms25052546

IF: 5.6

2024-02-23

International Journal of Molecular Sciences

Abstract:Major strides have been made in the development of FLASH radiotherapy (FLASH RT) in the last ten years, but there are still many obstacles to overcome for transfer to the clinic to become a reality. Although preclinical and first-in-human clinical evidence suggests that ultra-high dose rates (UHDRs) induce a sparing effect in normal tissue without modifying the therapeutic effect on the tumor, successful clinical translation of FLASH-RT depends on a better understanding of the biological mechanisms underpinning the sparing effect. Suitable in vitro studies are required to fully understand the radiobiological mechanisms associated with UHDRs. From a technical point of view, it is also crucial to develop optimal technologies in terms of beam irradiation parameters for producing FLASH conditions. This review provides an overview of the research progress of FLASH RT and discusses the potential challenges to be faced before its clinical application. We critically summarize the preclinical evidence and in vitro studies on DNA damage following UHDR irradiation. We also highlight the ongoing developments of technologies for delivering FLASH-compliant beams, with a focus on laser-driven plasma accelerators suitable for performing basic radiobiological research on the UHDR effects.

biochemistry & molecular biology,chemistry, multidisciplinary
Failure of Parathormone to Affect Insulin and Glucagon Release from the Perfused Rat Pancreas

O. Rebolledo,V. Leclercq-Meyer,J. Marchand,R. Leclercq,W. Malaisse

DOI: https://doi.org/10.1055/s-0028-1093756

1975-07-01

Abstract:Parathormone (0.15 U/ml) failed to affect the rate of glucagon and insulin release by the perfused rat pancreas exposed to glucose in either low (3.3 mM) or high (8.3 mM) concentration. Parathormone also failed to interfere with the suppressive effect of glucose (16.6mM) upon glucagon release and its stimulatory action upon insulin secretion. Likewise, the biphasic release of both glucagon and insulin evoked by arginine (10.0 mM) in the presence of glucose (8.3 mM) was unaffected by parathormone. These findings suggest that the endocrine pancreas may not be a target organ for any direct and immediate action of parathormone.
A multidisciplinary view of flash irradiation

Flavia Gesualdi,Ludovic de Marzi,Marie Dutreix,Vincent Favaudon,Charles Fouillade,Sophie Heinrich

DOI: https://doi.org/10.1016/j.canrad.2024.07.003

Abstract:The delivery of ultra-high dose rates of radiation, called flash irradiation or flash-RT, has emerged as a new modality of radiotherapy shaking up the paradigm of proportionality of effect and dose whatever the method of delivery of the radiation. The hallmark of flash-RT is healthy tissue sparing from the side effects of radiation without decrease of the antitumor efficiency in animal models. In this review we will define its specificities, the molecular mechanisms underlying the flash effect and the ongoing developments to bring this new modality to patient treatment.

[Effect of pressure on palatal soft tissue: histological study].

Transformative Technology for FLASH Radiation Therapy: A Snowmass 2021 White Paper

FLASH: New intersection of physics, chemistry, biology, and cancer medicine

FLASH Radiation Therapy — Key physical irradiation parameters and beam characteristics

Framework for Quality Assurance of Ultra-High Dose Rate Clinical Trials Investigating FLASH Effects and Current Technology Gaps

A potential revolution in cancer treatment: A topical review of FLASH radiotherapy

FLASH Radiotherapy: History and Future

Navigating the Critical Translational Questions for Implementing FLASH in the Clinic

Effect of tight junctional resistance on penetration of LLC-PK1 epithelial cell layers by metastatic B16-F10 melanoma cells.

Ultrahigh dose-rate (FLASH) x-ray irradiator for pre-clinical laboratory research

FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?

The FLASH effect—an evaluation of preclinical studies of ultra-high dose rate radiotherapy

Immunoglobulins and complement factors in senile plaques

FLASH radiotherapy: ultra-high dose rates to spare healthy tissue

Dosimetry for FLASH Radiotherapy: A Review of Tools and the Role of Radioluminescence and Cherenkov Emission

Emergence of FLASH‐radiotherapy across the last 50 years (Review)

FLASH radiotherapy: A new milestone in the field of cancer radiotherapy

Democratizing FLASH Radiotherapy

Expectations, Challenges, and Current Knowledge

Failure of Parathormone to Affect Insulin and Glucagon Release from the Perfused Rat Pancreas

A multidisciplinary view of flash irradiation